ABSTRACT:
ABSTRACT:
Objective: To directly compare the effectiveness of the highest approved doses of two sodium-glucose co-transporter 2 (SGLT2) inhibitors Empagliflozin and Dapagliflozin as part of Dual oral antidiabetic agents in type 2 diabetes (T2DM) patients. Methods: This study was a randomized, triple-blind, crossover, 24-week monocenter Trial. T2D Patients were randomized to receive metformin 1000mg b.i.d with Empagliflozin 25 mg/day and then metformin 1000mg b.i.d with Dapagliflozin 10mg/day (n=24) or vice versa (n=23). Each treatment period was 12 weeks with a 10-day washout period in between (without stopping metformin). The parameters evaluated at baseline and after 12 and 24 weeks. The primary outcome was the mean change from baseline in haemoglobin A1c (HbA1C), Fasting Blood Glucose (FBG), Body Mass Index (BMI), Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP). Analyses were done per the Per-protocol principle. Results: Empagliflozin administration showed significant reductions in HBA1C, FBG, BMI, SBP and DBP (p>0.05), Dapagliflozin administration improved the levels of HBA1C, FBG, BMI, SBP and DBP but it was significant only in FBG (p=0.001) and SBP (p=0.035). There were no significant changes from baseline in HbA1c, FBG, SBP and DBP with Empagliflozin treatment compared with Dapagliflozin (P<0.05). Both groups showed reductions in BMI but the reduction was greater in the Empagliflozin group (between groups; p=0,044). Conclusions: This study showed that SGLT2 inhibitors can be effectively used as dual oral antidiabetic agents in T2D patients who are treated with metformin. More specifically, Empagliflozin was more effective in reducing BMI.
Cite this article:
Nihad Kharrat Helu*, Abdulhakim Nattouf. A Comparison of Efficacy among Syrian diabetic patients treated with Empagliflozin versus Dapagliflozin, a Randomized, Triple-blind, Two-period crossover study. Research Journal of Pharmacy and Technology 2023; 16(10):4642-8. doi: 10.52711/0974-360X.2023.00755
Cite(Electronic):
Nihad Kharrat Helu*, Abdulhakim Nattouf. A Comparison of Efficacy among Syrian diabetic patients treated with Empagliflozin versus Dapagliflozin, a Randomized, Triple-blind, Two-period crossover study. Research Journal of Pharmacy and Technology 2023; 16(10):4642-8. doi: 10.52711/0974-360X.2023.00755 Available on: https://rjptonline.org/AbstractView.aspx?PID=2023-16-10-25
REFERENCES:
1. Saeedi, P., Petersohn, I., Salpea, P. and Malanda, B. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045 : results from the International Diabetes Federation Diabetes Atlas , 9 th edition. Diabetes Res. Clin. Pract. 2019; 11(157):107843. doi:10.1016/j.diabres.2019.107843.
2. Naveen K L, Grinton Josvi Veigas, Ananya Bhattacharjee. Patient with Diabetes Mellitus and Ocular Complications: A Brief review. Asian Journal of Pharmacy and Technology. 2021; 11(2):141-5. doi: 10.52711/2231-5713.2021.00023.
3. Bairagi G.B., Kabra A.O., Mandade R.J. Sexual Dysfunction in Men with Diabetes Mellitus. Research J. Pharm. and Tech. 2011; 4(5): 677-684.
4. Vyasa, B. Cardiovascular Death: Leading cause of death in Diabetes. Research J. Pharmacology and Pharmacodynamics. 2013; 5(4): 249-256.
5. Parisa Parsa, Roya Ahmadinia-Tabesh, Younes Mohammadi. Assessment of the risk of Coronary Heart Disease in Diabetes Patients Type-II. Asian J. Nursing Education and Research. 2019; 9(2):267-270. doi: 10.5958/2349-2996.2019.00057.0
6. Indrayani D. Raut, Akshada N. Kakade , Jadhav Snehal, Jadhav Priyanka, Kabir Amruta. Survey on Antidiabetic Drugs. Res. J. Pharmacology and Pharmacodynamics.2017; 9(1): 10-12. doi: 10.5958/2321-5836.2017.00002.7
7. Dewangan, V. and Pandey, H. Pathophysiology and Management of Diabetes: A Review. Res. J. Pharmacology and Pharmacodynamics.2016; 8(3): 219-222. doi: 10.5958/2321-5836.2017.00039.8
8. Ishan Panchal, B Panigrahi, CN Patel. Recent Advancement towards Treatment of Diabetes. Research J. Pharmacology and Pharmacodynamics. 2010; 2(1):12-22.
9. Saidha, K. and Keer, V. Management of Diabetes: A Review. Research J. Pharm. and Tech. 2014; 7(9): 1065–1072
10. Brunton, S. A. Hypoglycemic Potential of Current and Emerging Pharmacotherapies in Type 2 Diabetes Mellitus. Postgrad Med. 2012; 124(4):74-83. doi: 10.3810/pgm.2012.07.2570.
11. Sujatha Kumari, M., Kiran Rehana, M. and Sultana, R. Diabetes Mellitus: Present status and Drug therapy Updates. Research J. Pharm. and Tech. 2014; 7(1): 84-94
12. Chao, E. C. and Henry, R. R. SGLT2 inhibition-A novel strategy for diabetes treatment. Nat. Rev. Drug Discov. 2010; 9, 551–559.
13. Li J, Gong Y, Li C, Lu Y, Liu Y, Shao Y. Long-term efficacy and safety of sodium-glucose cotransporter-2 inhibitors as add-on to metformin treatment in the management of type 2 diabetes mellitus: A meta-analysis. Medicine (Baltimore). 2017 Jul;96(27):e7201. doi: 10.1097/MD.0000000000007201.
14. Kumar, R. S. SGLT-2 Inhibitors- Hope or Hype? - An updated Review. Asian J. Pharm. Res. 2021; 11(1):29-38. doi: 10.5958/2231-5691.2021.00007.1
15. Ferrannini E, Baldi S, Frascerra S, Astiarraga B, Barsotti E, Clerico A, Muscelli E. Renal Handling of Ketones in Response to Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 2 Diabetes. Diabetes Care. 2017;40(6):771-776. doi: 10.2337/dc16-2724.
16. Kadowaki T, Haneda M, Inagaki N, Terauchi Y, Taniguchi A, Koiwai K, Rattunde H, Woerle HJ, Broedl UC. Empagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, 12-week, double-blind, placebo-controlled, phase II trial. Adv Ther. 2014; 31(6):621-38. doi: 10.1007/s12325-014-0126-8
17. Häring HU, Merker L, Seewaldt-Becker E, Weimer M, Meinicke T, Broedl UC, Woerle HJ; EMPA-REG MET Trial Investigators. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care. 2014; 37(6):1650-9. doi: 10.2337/dc13-2105
18. Rosenstock J, Seman LJ, Jelaska A, Hantel S, Pinnetti S, Hach T, Woerle HJ. Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia. Diabetes Obes Metab. 2013 Dec;15(12):1154-60. doi: 10.1111/dom.12185.
19. Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care. 2010 Oct;33(10):2217-24. doi: 10.2337/dc10-0612.
20. Kaku K, Inoue S, Matsuoka O, Kiyosue A, Azuma H, Hayashi N, Tokudome T, Langkilde AM, Parikh S. Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2013 May;15(5):432-40. doi: 10.1111/dom.12047.
21. Ji L, Ma J, Li H, Mansfield TA, T'joen CL, Iqbal N, Ptaszynska A, List JF. Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study. Clin Ther. 2014 Jan 1;36(1):84-100.e9. doi: 10.1016/j.clinthera.2013.11.002
22. Huang H, Bell KF, Gani R, Tugwell CW, Eudicone JM, Krukas-Hampel MR. A retrospective real-world study of dapagliflozin versus other oral antidiabetic drugs added to metformin in patients with type 2 diabetes. Am J Manag Care. 2018 Apr;24(8 Suppl):S132-S137
23. Bolinder J, Ljunggren Ö, Johansson L, Wilding J, Langkilde AM, Sjöström CD, Sugg J, Parikh S. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab. 2014 Feb;16(2):159-69. doi: 10.1111/dom.12189
24. Bailey CJ, Gross JL, Hennicken D, Iqbal N, Mansfield TA, List JF. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Med. 2013 Feb 20;11:43. doi: 10.1186/1741-7015-11-43.
25. Ku EJ, Lee DH, Jeon HJ, Oh TK. Empagliflozin versus dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin, glimepiride and dipeptidyl peptide 4 inhibitors: A 52-week prospective observational study. Diabetes Res Clin Pract. 2019 May;151:65-73. doi: 10.1016/j.diabres.2019.04.008.
26. Ferrannini E, Seman L, Seewaldt-Becker E, Hantel S, Pinnetti S, Woerle HJ. A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes. Diabetes Obes Metab. 2013 Aug;15(8):721-8. doi: 10.1111/dom.12081.
27. Bailey, C. J., Iqbal, N. and List, J. F. Dapagliflozin monotherapy in drug-na¨ıve patients with diabetes: a randomized-controlled trial of low-dose rang. Diabetes, Obes. Metab. 2012 Oct;14(10):951-9. doi: 10.1111/j.1463-1326.2012.01659.x.
28. Scheerer MF, Rist R, Proske O, Meng A, Kostev K. Changes in HbA1c, body weight, and systolic blood pressure in type 2 diabetes patients initiating dapagliflozin therapy: a primary care database study. Diabetes Metab Syndr Obes. 2016 Oct 31;9:337-345. doi: 10.2147/DMSO.S116243.
29. Bolinder J, Ljunggren Ö, Kullberg J, Johansson L, Wilding J, Langkilde AM, Sugg J, Parikh S. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012 Mar;97(3):1020-31. doi: 10.1210/jc.2011-2260.
30. Bonora BM, Avogaro A, Fadini GP. Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence. Diabetes Metab Syndr Obes. 2020;13:161-174. Published 2020 Jan 21. doi:10.2147/DMSO.S233538
31. Wilding J, Bailey C, Rigney U, Blak B, Kok M, Emmas C. Dapagliflozin therapy for type 2 diabetes in primary care: Changes in HbA1c, weight and blood pressure over 2 years follow-up. Prim Care Diabetes. 2017 Oct;11(5):437-444. doi: 10.1016/j.pcd.2017.04.004.
32. Liakos A, Karagiannis T, Athanasiadou E, Sarigianni M, Mainou M, Papatheodorou K, Bekiari E, Tsapas A. Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2014 Oct;16(10):984-93. doi: 10.1111/dom.12307.
33. Rosenstock, J. Marquard J, Laffel LM, Neubacher D.et al . Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes : The EASE Trials. Diabetes Care .(2018); 41, 2560–2569.
34. Packer M, Anker S, Butler J, Filippatos G.et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. new Engl. J. Med.2020;383:1413-1424. doi:10.1056/NEJMoa2022190.
35. Bonora BM, Avogaro A, Fadini GP. Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence. Diabetes Metab Syndr Obes. 2020;13:161-174
36. Dutka, M., Bobiński, R., Ulman, I., Maciej, W. and Jan, H. Sodium glucose cotransporter 2 inhibitors : mechanisms of action in heart failure. Heart Fail. Rev. 2020; 26(3): 603-622. doi:10.1007/s10741-020-10041-1.